January 22, 2021

Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch

Vaxess Technologies, Inc., an innovative biotechnology company developing the MIMIX™ smart release patch, was awarded a grant from the National Science Foundation (NSF award number 2030305) and a subcontract from the Defense Advanced Research Projects Agency (DARPA), a branch of the US Department of Defense, to advance two separate projects aimed at developing mRNA-based vaccines and other medical countermeasures with the following features:

  • Refrigeration-free, using the patented Silk Protein Matrix stabilization technology
  • Single dose administration, enabled by MIMIX™ sustained release formulation
  • Painless application via MIMIX™ skin patch

The patch is also compatible with a wide range of COVID-19 vaccine candidates, as demonstrated by Vaxess’ work towards a combination seasonal protection patch that includes both a COVID-19 vaccine and a broadly protective seasonal flu vaccine.

In 2013, Vaxess Technologies was awarded an Accelerator Loan. The Accelerator Loan Program was created by the MLSC as a funding program intended for early-stage life sciences companies in Massachusetts.